Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; triethyl citrate; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; povidone; magnesium stearate; citric acid; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; indigo carmine; sunset yellow fcf; allura red ac; polyvinyl alcohol; macrogol 3350; xanthan gum; lecithin - epilepsy. primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.. mania. for the treatment of mania where other therapy has proved inadequate or is inappropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - sodium valproate 100 mg/ml - solution for injection - 100 mg/ml - active: sodium valproate 100 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic potassium phosphate water for injection - the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

United Kingdom - English - myHealthbox

wockhardt uk ltd - sodium valproate - liquid for oral use - 40mg/ml - antiepileptics - in the treatment of generalised, partial or other epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

United Kingdom - English - myHealthbox

wockhardt uk ltd - sodium valproate - enteric coated tablet - 200mg - antiepileptics - in the treatment of generalised, partial or other epilepsy.

United Kingdom - English - myHealthbox

wockhardt uk ltd - sodium valproate - enteric coated tablet - 500mg - antiepileptics - in the treatment of generalised, partial or other epilepsy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - sodium valproate - gastro-resistant tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - sodium valproate - gastro-resistant tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - sodium valproate - oral solution - 40mg/1ml